Comedication of caspofungin acetate and cyclosporine A after allogeneic haematopoietic stem cell transplantation leads to negligible hepatotoxicity

Mycoses

Volumn 51, Issue SUPPL. 1, 2008, Pages 19-24

  Christopeit, Maximilian ^a   Eikam, Martin ^a   Behre, Gerhard ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Allogenic; Caspofungin; Cyclosporine A; Echinocandin; Hepatoxicity; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CASPOFUNGIN; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER TOXICITY; MALE; MEDICAL RECORD REVIEW; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CYCLOSPORINE; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS, TOXIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYCOSES; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 43549106588     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2008.01524.x     Document Type: Article

References (8)

1. Storb R, Deeg HJ, Pepe M et al. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. Br J Haematol 1989 72 : 567 72.
2. Maertens J, Raad I, Petrikkos G et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004 39 : 1563 71 Epub 9 November 2004 J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002 347 : 2020 9.
3. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004 351 : 1391 402.
4. Sanz-Rodriguez C, Arranz R, Cisneros JM et al. Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics. Swiss Med Wkl 2005 135 : 658 9.
5. Sanz-Rodriguez C, Lopez-Duarte M, Jurado M et al. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections. Bone Marrow Transplan 2004 34 : 13 20.
6. Marr KA, Hachem R, Papanicolaou G et al. Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Di 2004 6 : 110 6.
7. Trenschel R, Ditschkowski M, Elmaagacli AH et al. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation. Bone Marrow Transplan 2005 35 : 583 6.
8. Glasmacher A, Cornely OA, Orlopp K et al. Caspofungin treatment in severely ill, immunocompromised patients: a case-documentation study of 118 patients. J Antimicrob Chemothe 2006 57 : 127 34 Epub 24 November 2005 ].